share_log

賽生藥業：截至2023年12月31日之股份發行人的證券變動月報表

SCICLONE PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023

香港交易所 ·  Jan 5 04:08
Summary by Moomoo AI
賽生藥業於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持不變，總額為50,000美元，每股面值0.00005美元，總股份數目為1,000,000,000股。在股份期權方面，根據賽生藥業的股份期權計劃，公司於當月行使了10,475,300股份期權，並因此獲得了20,464,532.92港元的資金。該行使期權涉及的兩個計劃分別為購股權激勵計劃和首次公開發售後購股權計劃，分別於2018年6月24日和2021年1月22日獲得股東大會通過。報告中未提及其他類型的證券變動，並確認所有相關法律文件均已遵守並存檔。
賽生藥業於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持不變，總額為50,000美元，每股面值0.00005美元，總股份數目為1,000,000,000股。在股份期權方面，根據賽生藥業的股份期權計劃，公司於當月行使了10,475,300股份期權，並因此獲得了20,464,532.92港元的資金。該行使期權涉及的兩個計劃分別為購股權激勵計劃和首次公開發售後購股權計劃，分別於2018年6月24日和2021年1月22日獲得股東大會通過。報告中未提及其他類型的證券變動，並確認所有相關法律文件均已遵守並存檔。
Sai Sang Pharmaceuticals filed with Hong Kong Trading and Clearing Limited on 5 January 2024 with the Securities Movements Monthly Report for the year ended 31 December 2023. The report showed that the company's regulated/registered share capital remained unchanged, totaling $50,000, with a face value of $0.00005 per share, and the total number of shares was 1,000,000,000 shares. In terms of share options, the Company exercised 10,475,300 share options in the same month under Saiseng Pharmaceuticals' share option scheme and thus received funding of HK$20,464,532.92. The two schemes involved in the exercise of the option are the Share Option Incentive Scheme and the Initial Public Offering Possession, which were approved by the General Meeting on 24 June 2018 and 22 January 2021 respectively. The report does not mention changes in other types of securities and confirms that all relevant legal documents have been complied with and archived.
Sai Sang Pharmaceuticals filed with Hong Kong Trading and Clearing Limited on 5 January 2024 with the Securities Movements Monthly Report for the year ended 31 December 2023. The report showed that the company's regulated/registered share capital remained unchanged, totaling $50,000, with a face value of $0.00005 per share, and the total number of shares was 1,000,000,000 shares. In terms of share options, the Company exercised 10,475,300 share options in the same month under Saiseng Pharmaceuticals' share option scheme and thus received funding of HK$20,464,532.92. The two schemes involved in the exercise of the option are the Share Option Incentive Scheme and the Initial Public Offering Possession, which were approved by the General Meeting on 24 June 2018 and 22 January 2021 respectively. The report does not mention changes in other types of securities and confirms that all relevant legal documents have been complied with and archived.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more